which would build a temporary database of information collected by States on newly hired employees for matching activities with cases in locate status within the FPLS and cases certified for Federal tax refund offset. This collection responds to President Clinton's June 18, 1996, executive action on welfare reform announcing a new pilot program that will help track those parents who cross state lines to avoid their child support obligation.

Under the pilot, States which currently have new hire reporting programs in place would voluntarily send their existing record data via computer tape, formatted according to either the State's or Administration for Children and Families's (ACF) specifications, to the Federal Parent Locate Service within OCSE. These records will be stored in a temporary database to be matched against case data in the FPLS, and the Tax Refund Offset System (TROS).

When a match is made, the ACF Office will contact the absent parent's current state of residence where a match was found so that the state child support agency can take appropriate action. In turn, States will be asked to submit periodic tracking and reporting information on the success of the pilot matching.

Respondents: State governments.

Annual Burden Estimates:

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Standard Forms	25	1	8	200

Estimated Total Annual Burden Hours: 200.

Explanation

- The specific number of estimated annual burden hours per State will vary depending on individual circumstances, including systems development effort and number of records.
- Burden hours for employees and employers are not considered as part of this request. Most of the information has been collected from employees and employers under the IRS new hire, Form W–4 (OMB Control No. 1545–0010), and/or comparable State forms. In addition, ACF will not collect any more information from employers or employees under this pilot project than what States have already collected.

Additional Information

ACF is requesting that OMB grant a 90 day approval for this information collection under procedures for emergency processing by July 11, 1996. A copy of this information collection, with applicable supporting documentation, may be obtained by calling the Administration for Children and Families, Reports Clearance Officer, Bob Sargis at (202) 401–6465.

Comments and questions about the information collection described above should be directed to Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project, 725 17th Street N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor, (202) 395–7316.

Dated: June 24, 1996.

Larry Guerrero,

Director, Office of Information Management Services.

[FR Doc. 96–16569 Filed 6–27–96; 8:45 am]

BILLING CODE 4184–01–M

Health Care Financing Administration

[HCFA–2744, HCFA–2746]

Agency Information Collection Activities: Submission for OMB Review; Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposal for the collection of information. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Information Collection Request:* Reinstatement, with change, of a previously approved collection for which approval has expired; *Title of Information Collection:* End Stage Renal Disease Medical Information System ESRD Facility Survey; *Form No.:* HCFA–2744; *Use:* The ESRD Facility Survey form is completed annually by Medicare approved providers of dialysis and transplant services. The HCFA–2744 is designed to collect information concerning treatment trends, utilization of services and patterns of practice in treating ESRD patients. *Frequency:* Annually; *Affected Public:* Business or other for-profit and Not-for-profit institutions; *Number of Respondents:* 3,200; *Total Annual Responses:* 3,200; *Total Annual Hours Requested:* 25,600.

2. *Type of Information Collection Request:* Reinstatement, with change, of a previously approved collection for which approval has expired; *Title of Information Collection:* End Stage Renal Disease Death Notification; *Form No.:* HCFA–2746; *Use:* The form is completed by all Medicare approved ESRD facilities upon the death of an ESRD patient. Its primary purpose is to collect fact and cause of death. Reports of deaths are used to show cause of death and demographic characteristics of these patients. *Frequency:* On occasion; *Affected Public:* Business or other for-profit, Not-for-profit institutions and Federal Government; *Number of Respondents:* 2,900; *Total Annual Responses:* 40,600; *Total Annual Hours Requested:* 6,902.

To request copies of the proposed paperwork collections referenced above, E-mail your request, including your address, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections should be sent within 30 days of this notice directly to the OMB Desk Officer designated at the following address: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: June 20, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 96–16604 Filed 6–27–96; 8:45 am]

BILLING CODE 4120–03–P

National Institutes of Health

National Cancer Institute: Opportunities for Cooperative Research and Development Agreements (CRADA) for the Development of Green Fluorescent Protein (GFP) Technology Applications

Currently the National Cancer Institute (NCI) has identified at least five applications for this technology; GFP research products, gene therapy gene expression, analysis, diagnostics, and drug screening. The NCI is looking for multiple CRADA Collaborators to develop independently different aspects of the GFP technology.

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice.

SUMMARY: Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. 3710; Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer and Advancement Act of 1995), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public Health Service (PHS) of the Department of Health and Human Services (DHHS) seeks Cooperative Research and Development Agreements (CRADA) with pharmaceutical or biotechnology companies to develop application of GFP. Any CRADA for the biomedical use of this technology will be considered. The CRADAs would have an expected duration of one (1) to five (5) years. The goals of the CRADAs include the rapid publication of research results and their timely commercialization of products, diagnostics and treatments that result from the research. The CRADA Collaborators will have an option to negotiate the terms of an exclusive or nonexclusive commercialization license to subject inventions arising under the CRADAs.

ADDRESSES: Proposals and questions about these CRADA opportunities may be addressed to Steven P. Marquis, Office of Technology Development, National Cancer Institute-Frederick Cancer Research and Development Center, P.O. Box B, Frederic, MD 21702–1201, Telephone: (301) 846–5465, Facsimile: (301) 846–6820. Background information, including abstracts and reprints, is available. In addition, pertinent information not yet publicly disclosed may be obtained under a confidential disclosure agreement.

Requests for license application form, or other questions and comments concerning the licensing of this technology should be directed to Steven M. Ferguson, Acting Chief, Infectious Disease Branch, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804, Telephone: (301) 496–7735 ext. 266, Facsimile: (301) 402–0220. A signed confidentiality agreement will be required to receive confidential information.

EFFECTIVE DATE: In view of the high interest for developing GFP for applications and diagnostics, interested parties should notify the NCI Office of Technology Development in writing no later than thirty (30) days from the date of this announcement. Respondents will then be provided an additional thirty (30) days for submitting formal CRADA proposals.

SUPPLEMENTARY INFORMATION: The Green Fluorescent Protein (GFP) from the jellyfish Aequorea Victoria is rapidly becoming an important reporter molecule for monitoring gene expression in vivo, in situ and in real time GFP emits a green light when excited with UV light. Unlike other bioluminescent reporters, GFP fluoresces in the absence of any other proteins, substrates, or cofactors. Currently there are several improved mutations of the GFP, which allow for sufficient detection of gene expression in various species cells, However, the current technology, in contrast to the wild type protein or other reported mutants allows detection of green fluorescence in living mammalian cells when present in few copies stably integrated into the genome. The current mutation increases the intensity of the fluorescent signal by more than tenfold over that of the wild type protein, which provide a fluorescence signal visible in mammalian cells.

A U.S. Patent Application has been filed for this technology by the DHHS and is currently pending. Parties interested in submitting a CRADA proposal should be aware that it may be necessary to secure a license to this patent application in order to commercialize products arising from the CRADA.

The role of the National Cancer Institute in this CRADA will include, but not be limited to:

1. Providing intellectual, scientific, and technical expertise and experience to the research project.

2. Planning research studies and interpreting research results.

3. Contracting, as needed, support services at the NCI–FCRDC such as antigen and antibody production.

4. Publishing research results.

The role of the CRADA Collaborator may include, but not limited to:

1. Providing significant intellectual, scientific, and technical expertise or experience to the research project.

2. Planning research studies and interpreting research results.

3. Providing support for ongoing CRADA-related research in the development of the particular application of GFP technology.

(a) Financial support to facilitate scientific goals;

(b) Technical or financial support for further design of applications.

4. Publishing research results.

Selection criteria for choosing the CRADA Collaborator may include, but not to be limited to:

1. The ability to collaborate with NCI on further research and development of this technology. This ability can be demonstrated through experience and expertise in this or related areas of technology indicating the ability to contribute intellectually to ongoing research and development.

2. The demonstration of adequate resources to perform the research, development and commercialization of this technology (e.g. facilities, personnel and expertise) and accomplish objectives according to an appropriate timetable to be outlined in the CRADA Collaborator's proposal.

3.The willingness to commit best effort and demonstrated resources to the research, development and commercialization of this technology.

4. The demonstration of expertise in the commercial development, production, marketing and sales of products related to this area of technology.

5. The level of financial support the CRADA Collaborator will provide for CRADA-related Government activities.

6. The willingness to cooperate with the National Cancer Institute in the timely publication of research results.

7. The agreement to be bound by the appropriate DHHS regulations relating to human subjects, and all PHS policies relating to the use and care of laboratory animals.

8. The willingness to accept the legal provisions and language of the CRADA with only minor modifications, if any. These provisions govern the equitable distribution of patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor, with (1) the grant of a license for research and other Government purpose to the Government when the CRADA Collaborator's employee is the sole inventor, or (2) the grant of an option to elect an exclusive or

nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor.

Dated: June 18, 1996.

Thomas D. Mays,

Director, Office of Technology Development, National Cancer Institute, National Institutes of Health.

[FR Doc. 96–16493 Filed 6–27–96; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institutes; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Cancer Institute Initial Review Group:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: Subcommittee D—Clinical Studies Subcommittee.

Dates: July 29–30, 1996.

Time: 8 a.m.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: John W. Abrell, Ph.D., 6130 Executive Blvd., Room 635B, Bethesda, MD 20892, Telephone: 301–496–9767.

Committee Name: Subcommittee E—Prevention and Control Subcommittee.

Date: July 30, 1996.

Time: 9 a.m.

Place: Hyatt Regency Hotel, One Bethesda Metro, Bethesda, MD 20852.

Contact Person: Sally A. Mulhern, Ph.D., 6130 Executive Blvd., Room 643G, Bethesda, MD 20892, Telephone: 301–496–7413.

Committee Name: Subcommittee C—Basic and Preclinical Sciences Subcommittee.

Dates: July 31–August 2, 1996.

Time: July 31–7:30 p.m.—August 1–2–8 a.m.

Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, N.W., Washington, D.C. 20007.

Contact Person: Virginia P. Wray, Ph.D., 6130 Executive Blvd., Room 635, Bethesda, MD 20892, Telephone: 301–496–9236.

Committee Name: Subcommittee A—Cancer Centers Subcommittee.

Dates: August 1–2, 1996.

Time: 8 a.m.

Place: The Bethesda Ramada, 8400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: David E. Maslow, Ph.D., 6130 Executive Blvd., Room 643A, Bethesda, MD 20892, Telephone: 301–496–2330.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: June 21, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–16492 Filed 6–27–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Dental Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Dental Research Special Emphasis Panel (SEP) meetings:

Name of SEP: National Institute of Dental Research Special Emphasis Panel—Review of RFP No. NLM 96–100/MLM (96–35).

Dates: July 15–16, 1996.

Time: 8:00 a.m.

Place: Holiday Inn/Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact person: Dr. George Hausch, Chief, Grants Review Section, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

Name of SEP: National Institute of Dental Research Special Emphasis Panel—Project Site Visit (96–30).

Dates: July 18–19, 1996.

Time: 8:00 a.m.

Place: San Francisco Downtown Marriott, 55 Fourth Street, San Francisco, CA 94103.

Contact Person: Dr. George Hausch, Chief, Grants Review Section, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

Name of SEP: National Institute of Dental Research Special Emphasis Panel—Review of R44's (96–28)

Dates: July 30, 1996.

Time: 12:00 Noon.

Place: National Institutes of Health, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (Teleconference).

Contact person: Dr. George Hausch, Chief, Grants Review Section, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

Name of SEP: National Institute of Dental Health Research Special Emphasis Panel—Review of RFA DE–96–003 (96–31).

Dates: August 5–6, 1996.

Time: 8:00 a.m.

Place: Cross Keys Inn, 5100 Falls Road, Baltimore, MD 21210.

Contact person: Dr. Yong Shin, Grants Review Section, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.121, Oral Diseases and Disorders Research)

Dated: June 21, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–16491 Filed 6–27–96; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–3454–N–02]

Office of the Assistant Secretary for Housing-Federal Housing Commissioner; Capital Improvement Loans Under the Flexible Subsidy Program Awarded as Incentives Pursuant to Preservation Plans of Action, Announcement of Funding Awards; Fiscal Year 1993

AGENCY: Office of the Assistant Secretary for Housing - Federal Housing Commissioner, HUD.

ACTION: Announcement of funding awards.

SUMMARY: In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this announcement notifies the public of funding awards made by the Department for funding under a Federal Register Notice of Funding Availability (NOFA) for the Capital Improvement Loan Program. This announcement contains the names and addresses of the awardees and the amount of the awards.

FOR FURTHER INFORMATION CONTACT: Ruth Coward, Program Support Division, Office of Multifamily Asset Management and Disposition, Office of Housing, Department of Housing and Urban Development, 451 Seventh Street, SW, Washington, DC 20410, telephone (202) 708–2654. (This is not a toll-free number.) Hearing- or speech-impaired individuals may access this number by calling the Federal Information Relay Service TTY at 1–800–877–8339.

SUPPLEMENTARY INFORMATION: The Flexible Subsidy Program is authorized